Correlation of cytochrome p450 (CYP) ia2 activity using caffeine phenotyping and olanzapine disposition in healthyvolunteers

Kara Lee Shirley, Yuen Y. Hon, Scott R. Penzak, Y. W. Francis Lam, Vicky Spratlin, Michael W. Jann

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Olanzapine has previously been shown to have predominant metabolism by cytochrome (CYP) P450 IA2. Caffeine has been shown to provide an accurate phenotypic probe for measuring CYP1A2 activity. The purpose ofthis study is to determine if a significant correlationexists between olanzapine disposition and caffeine metabolic ratios. Subjects were phenotyped for CYP1A2 activity with caffeine probemethodology. After 200-mg caffeine administration, blood (4 h), saliva (6 and 10 h), and urine (8 h total) were collected for highperformance liquid chromatography (HPLC) analysis of caffeine and its metabolites.CYP1A2 activity was measured as plasma (PMR^h), saliva (SMR6hand SMR10h), and three urinary metabolic (UMR18h, UMR28h, and UMR38h) ratios. Each ofthe 14 healthy nonsmokers(13 male) received a single 10 mg olanzapine dose after which blood was collected for HPLC determination of olanzapine concentrationsat predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96, and 120 h postdose. Olanzapine pharmacokinetic parameters in thisstudy were similar to those previously published. Allcaffeine metabolic ratios (PMR4h, SMR6h, SMR10h, UMR18h, and UMR28h)significantly correlated with each other (p<0.001) except for UMR38 h, which did not correlate. A significant correlation (p<0.05) wasalso found between olanzapine clearance and PMR_4h(r =0.701), SMR6h(r = 0.644), SMR10h(r = 0.701), UMR18h(r = 0.745), andUMR28h(r = 0.710). A negative correlation was observed between olanzapine clearance and UMR38h(r =0.029, p=NS). Asignificant correlation was found between olanzapine clearance and various caffeine metabolic ratios. Interpatient variability in CYP1A2activity may explain the wide interpatient variability in olanzapine disposition. Compounds that modulate CYP1A2 activity may beexpected to alter olanzapine pharmacokinetics accordingly.

Original languageEnglish (US)
Pages (from-to)961-966
Number of pages6
JournalNeuropsychopharmacology
Volume28
Issue number5
DOIs
StatePublished - May 2003

Fingerprint

olanzapine
Caffeine
Cytochrome P-450 Enzyme System
Cytochrome P-450 CYP1A2
Saliva
Liquid Chromatography
Pharmacokinetics
Cytochromes

Keywords

  • CYPIA2
  • Caffeine
  • Olanzapine
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Correlation of cytochrome p450 (CYP) ia2 activity using caffeine phenotyping and olanzapine disposition in healthyvolunteers. / Shirley, Kara Lee; Hon, Yuen Y.; Penzak, Scott R.; Francis Lam, Y. W.; Spratlin, Vicky; Jann, Michael W.

In: Neuropsychopharmacology, Vol. 28, No. 5, 05.2003, p. 961-966.

Research output: Contribution to journalArticle

Shirley, Kara Lee ; Hon, Yuen Y. ; Penzak, Scott R. ; Francis Lam, Y. W. ; Spratlin, Vicky ; Jann, Michael W. / Correlation of cytochrome p450 (CYP) ia2 activity using caffeine phenotyping and olanzapine disposition in healthyvolunteers. In: Neuropsychopharmacology. 2003 ; Vol. 28, No. 5. pp. 961-966.
@article{f3fe6910f7c14d9ba769e26797f62c17,
title = "Correlation of cytochrome p450 (CYP) ia2 activity using caffeine phenotyping and olanzapine disposition in healthyvolunteers",
abstract = "Olanzapine has previously been shown to have predominant metabolism by cytochrome (CYP) P450 IA2. Caffeine has been shown to provide an accurate phenotypic probe for measuring CYP1A2 activity. The purpose ofthis study is to determine if a significant correlationexists between olanzapine disposition and caffeine metabolic ratios. Subjects were phenotyped for CYP1A2 activity with caffeine probemethodology. After 200-mg caffeine administration, blood (4 h), saliva (6 and 10 h), and urine (8 h total) were collected for highperformance liquid chromatography (HPLC) analysis of caffeine and its metabolites.CYP1A2 activity was measured as plasma (PMR^h), saliva (SMR6hand SMR10h), and three urinary metabolic (UMR18h, UMR28h, and UMR38h) ratios. Each ofthe 14 healthy nonsmokers(13 male) received a single 10 mg olanzapine dose after which blood was collected for HPLC determination of olanzapine concentrationsat predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96, and 120 h postdose. Olanzapine pharmacokinetic parameters in thisstudy were similar to those previously published. Allcaffeine metabolic ratios (PMR4h, SMR6h, SMR10h, UMR18h, and UMR28h)significantly correlated with each other (p<0.001) except for UMR38 h, which did not correlate. A significant correlation (p<0.05) wasalso found between olanzapine clearance and PMR_4h(r =0.701), SMR6h(r = 0.644), SMR10h(r = 0.701), UMR18h(r = 0.745), andUMR28h(r = 0.710). A negative correlation was observed between olanzapine clearance and UMR38h(r =0.029, p=NS). Asignificant correlation was found between olanzapine clearance and various caffeine metabolic ratios. Interpatient variability in CYP1A2activity may explain the wide interpatient variability in olanzapine disposition. Compounds that modulate CYP1A2 activity may beexpected to alter olanzapine pharmacokinetics accordingly.",
keywords = "CYPIA2, Caffeine, Olanzapine, Pharmacokinetics",
author = "Shirley, {Kara Lee} and Hon, {Yuen Y.} and Penzak, {Scott R.} and {Francis Lam}, {Y. W.} and Vicky Spratlin and Jann, {Michael W.}",
year = "2003",
month = "5",
doi = "10.1038/sj.npp.1300123",
language = "English (US)",
volume = "28",
pages = "961--966",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Correlation of cytochrome p450 (CYP) ia2 activity using caffeine phenotyping and olanzapine disposition in healthyvolunteers

AU - Shirley, Kara Lee

AU - Hon, Yuen Y.

AU - Penzak, Scott R.

AU - Francis Lam, Y. W.

AU - Spratlin, Vicky

AU - Jann, Michael W.

PY - 2003/5

Y1 - 2003/5

N2 - Olanzapine has previously been shown to have predominant metabolism by cytochrome (CYP) P450 IA2. Caffeine has been shown to provide an accurate phenotypic probe for measuring CYP1A2 activity. The purpose ofthis study is to determine if a significant correlationexists between olanzapine disposition and caffeine metabolic ratios. Subjects were phenotyped for CYP1A2 activity with caffeine probemethodology. After 200-mg caffeine administration, blood (4 h), saliva (6 and 10 h), and urine (8 h total) were collected for highperformance liquid chromatography (HPLC) analysis of caffeine and its metabolites.CYP1A2 activity was measured as plasma (PMR^h), saliva (SMR6hand SMR10h), and three urinary metabolic (UMR18h, UMR28h, and UMR38h) ratios. Each ofthe 14 healthy nonsmokers(13 male) received a single 10 mg olanzapine dose after which blood was collected for HPLC determination of olanzapine concentrationsat predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96, and 120 h postdose. Olanzapine pharmacokinetic parameters in thisstudy were similar to those previously published. Allcaffeine metabolic ratios (PMR4h, SMR6h, SMR10h, UMR18h, and UMR28h)significantly correlated with each other (p<0.001) except for UMR38 h, which did not correlate. A significant correlation (p<0.05) wasalso found between olanzapine clearance and PMR_4h(r =0.701), SMR6h(r = 0.644), SMR10h(r = 0.701), UMR18h(r = 0.745), andUMR28h(r = 0.710). A negative correlation was observed between olanzapine clearance and UMR38h(r =0.029, p=NS). Asignificant correlation was found between olanzapine clearance and various caffeine metabolic ratios. Interpatient variability in CYP1A2activity may explain the wide interpatient variability in olanzapine disposition. Compounds that modulate CYP1A2 activity may beexpected to alter olanzapine pharmacokinetics accordingly.

AB - Olanzapine has previously been shown to have predominant metabolism by cytochrome (CYP) P450 IA2. Caffeine has been shown to provide an accurate phenotypic probe for measuring CYP1A2 activity. The purpose ofthis study is to determine if a significant correlationexists between olanzapine disposition and caffeine metabolic ratios. Subjects were phenotyped for CYP1A2 activity with caffeine probemethodology. After 200-mg caffeine administration, blood (4 h), saliva (6 and 10 h), and urine (8 h total) were collected for highperformance liquid chromatography (HPLC) analysis of caffeine and its metabolites.CYP1A2 activity was measured as plasma (PMR^h), saliva (SMR6hand SMR10h), and three urinary metabolic (UMR18h, UMR28h, and UMR38h) ratios. Each ofthe 14 healthy nonsmokers(13 male) received a single 10 mg olanzapine dose after which blood was collected for HPLC determination of olanzapine concentrationsat predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96, and 120 h postdose. Olanzapine pharmacokinetic parameters in thisstudy were similar to those previously published. Allcaffeine metabolic ratios (PMR4h, SMR6h, SMR10h, UMR18h, and UMR28h)significantly correlated with each other (p<0.001) except for UMR38 h, which did not correlate. A significant correlation (p<0.05) wasalso found between olanzapine clearance and PMR_4h(r =0.701), SMR6h(r = 0.644), SMR10h(r = 0.701), UMR18h(r = 0.745), andUMR28h(r = 0.710). A negative correlation was observed between olanzapine clearance and UMR38h(r =0.029, p=NS). Asignificant correlation was found between olanzapine clearance and various caffeine metabolic ratios. Interpatient variability in CYP1A2activity may explain the wide interpatient variability in olanzapine disposition. Compounds that modulate CYP1A2 activity may beexpected to alter olanzapine pharmacokinetics accordingly.

KW - CYPIA2

KW - Caffeine

KW - Olanzapine

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0038050712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038050712&partnerID=8YFLogxK

U2 - 10.1038/sj.npp.1300123

DO - 10.1038/sj.npp.1300123

M3 - Article

C2 - 12644842

AN - SCOPUS:0038050712

VL - 28

SP - 961

EP - 966

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 5

ER -